JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer

  • 0Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan; kokoro1979@gmail.com.
Anticancer Research +

|

February 2, 2024

|

February 2, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Serum CYFRA21-1 levels can predict outcomes in extensive disease-small cell lung cancer (ED-SCLC). High CYFRA21-1 levels correlate with shorter progression-free and overall survival in ED-SCLC patients receiving chemotherapy.

Area Of Science

  • Oncology
  • Biomarkers
  • Clinical Research

Background

  • Serum cytokeratin 19 fragment (CYFRA21-1) is a known prognostic marker in non-small cell lung cancer.
  • The prognostic value of CYFRA21-1 in small cell lung cancer (SCLC), particularly extensive disease (ED-SCLC), remains less understood.
  • This study investigates CYFRA21-1 as a potential prognostic tool in ED-SCLC.

Purpose Of The Study

  • To evaluate the prognostic significance of pretreatment serum CYFRA21-1 levels.
  • To determine the association between CYFRA21-1 levels and survival outcomes in ED-SCLC patients.
  • To assess the relationship between CYFRA21-1 levels and refractory relapse rates.

Main Methods

  • Retrospective analysis of 98 patients with extensive disease-small cell lung cancer (ED-SCLC).
  • Patients received first-line platinum-doublet chemotherapy.
  • Pretreatment serum CYFRA21-1 levels were measured and analyzed.

Main Results

  • Patients with high CYFRA21-1 levels (≥7.0 ng/ml) showed significantly shorter progression-free survival (PFS) and overall survival (OS).
  • Median PFS was 118 days for high CYFRA21-1 vs. 125 days for low (p=0.018).
  • Median OS was 213 days for high CYFRA21-1 vs. 295 days for low (p=0.046). High CYFRA21-1 was also linked to a higher refractory relapse rate.

Conclusions

  • Pretreatment serum CYFRA21-1 level is a potential prognostic marker for ED-SCLC patients.
  • This biomarker can help predict outcomes in patients undergoing platinum-doublet chemotherapy.
  • Further validation may establish CYFRA21-1 as a standard prognostic tool in SCLC.

Keywords: